Clinical Report: Early Fluid Resolution Predicts Faricimab Durability
Overview
Early resolution of retinal fluid in patients with neovascular age-related macular degeneration (nAMD) receiving faricimab therapy is associated with longer treatment intervals. This post hoc analysis of the TENAYA and LUCERNE trials indicates that rapid anatomical response may serve as a predictor of treatment durability.
Background
Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults, necessitating effective treatment strategies. Faricimab, a dual inhibitor of angiopoietin-2 and vascular endothelial growth factor A, has shown promise in extending treatment intervals while maintaining visual outcomes. Understanding predictors of treatment durability can help optimize patient management and reduce the burden of frequent injections.
Data Highlights
{'format': 'Ensure the table is properly formatted in the final document.'}Key Findings
- 265 out of 552 participants achieved early resolution of intraretinal and subretinal fluid.
- Patients with early fluid resolution had nearly twice the odds of receiving every-16-week dosing compared to every-8-week dosing.
- At week 112, those with early fluid resolution were more likely to remain on extended dosing intervals.
- Visual outcomes were comparable or slightly better in patients with early fluid resolution.
- Faricimab's dual mechanism may contribute to its rapid anatomical effects and treatment durability.
Clinical Implications
Clinicians may consider early fluid resolution as a potential marker for determining longer treatment intervals in patients receiving faricimab for nAMD. This could lead to reduced injection frequency, improving patient adherence and decreasing healthcare resource utilization.
Conclusion
The findings suggest that early anatomical response to faricimab therapy could guide treatment strategies in nAMD, potentially enhancing patient outcomes and reducing treatment burden.
References
- Retinal Physician, 2024 -- Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study
- Blood Cancer Journal, 2021 -- Reduction of free light chains shortly after starting treatment indicates positive prognosis in intact immunoglobulin myeloma
- Blood Cancer Journal, 2024 -- Impact of Adding IMiDs to Daratumumab in Multiple Myeloma Patients Resistant to Both Therapies: A Review of Immune Modulation and Synergistic Effects
- Ophthalmology | Vol 132, Issue 4, 2025 -- Clinical guidelines and consensus
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2 - PubMed
- retinal physician — Video: Faricimab Maintains Long-Term Stability in DME
- Efficacy of faricimab secondary to anti-vascular endothelial growth factor agents in patients with neovascular age-related macular degeneration: a systematic review and meta-analysis
- Ophthalmology | Vol 132, Issue 4, Pages A1-A20, P1-P344, e1-e78, 375-506 (April 2025) | ScienceDirect.com by Elsevier
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2 - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
